Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Homologous Recombination Repair Gene Mutation”

22 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 22 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03742895
What this trial is testing

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Who this might be right for
Advanced Solid Neoplasms
Merck Sharp & Dohme LLC 326
Not applicableStudy completedNCT04962880
What this trial is testing

HRR Prevalence in LatAm PROSPECT Study

Who this might be right for
Castration-resistant Prostate Cancer
AstraZeneca 388
Not applicableStudy completedNCT04425200
What this trial is testing

Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting

Who this might be right for
Prostatic Neoplasms
AstraZeneca 205
Testing effectiveness (Phase 2)Study completedNCT02873975
What this trial is testing

LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Who this might be right for
Advanced Cancers
Dana-Farber Cancer Institute 27
Not applicableNot Yet RecruitingNCT05901025
What this trial is testing

Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 5,000
Testing effectiveness (Phase 2)WithdrawnNCT03432676
What this trial is testing

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Who this might be right for
ATM Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+7 more
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)UnknownNCT04473339
What this trial is testing

Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerOvarian Cancer, Epithelial+2 more
CAI Hongbing 280
Testing effectiveness (Phase 2)Study completedNCT03377556
What this trial is testing

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
ATM Gene MutationATR Gene MutationBARD1 Gene Mutation+18 more
SWOG Cancer Research Network 51
Testing effectiveness (Phase 2)WithdrawnNCT06392841
What this trial is testing

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene Mutation+7 more
Qian Qin
Large-scale testing (Phase 3)Active Not RecruitingNCT04497844
What this trial is testing

Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Metastatic Castration-sensitive Prostate Cancer
Janssen Research & Development, LLC 696
Early research (Phase 1)Not Yet RecruitingNCT06614751
What this trial is testing

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Who this might be right for
Solid CancersBRCA MutationHRD Cancer+8 more
Danatlas Pharmaceuticals Co., Ltd 112
Not applicableStudy completedNCT05573789
What this trial is testing

Tumor Molecular Profiling in Patients With Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Prostate Adenocarcinoma
Hellenic Cooperative Oncology Group 220
Large-scale testing (Phase 3)Study completedNCT02987543
What this trial is testing

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 387
Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322
What this trial is testing

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Who this might be right for
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
UNICANCER 172
Testing effectiveness (Phase 2)Active Not RecruitingNCT04123366
What this trial is testing

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Who this might be right for
Solid Tumors
Merck Sharp & Dohme LLC 300
Early research (Phase 1)UnknownNCT04764084
What this trial is testing

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Who this might be right for
HER2-negative Breast CancerGastric AdenocarcinomaCholangiocarcinoma+1 more
Peking University Cancer Hospital & Institute 52
Large-scale testing (Phase 3)WithdrawnNCT02392676
What this trial is testing

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Who this might be right for
Platinum Sensitive Relapsed Ovarian Cancer
AstraZeneca
Not applicableUnknownNCT05310370
What this trial is testing

HRD and Resistance to PAPPi in EOC Patients

Who this might be right for
Epithelial Ovarian CancerHomologous Recombination DeficiencyHomologous Recombination Repair Gene Mutation+4 more
Lei Li 400
Testing effectiveness (Phase 2)Study completedNCT04174716
What this trial is testing

Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)

Who this might be right for
Solid TumorsHomologous Recombination Repair Gene MutationHomologous Recombination Deficiency
Idience Co., Ltd. 108
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Load More Results